Phase 2/3 Study of IGSC, 20% in PIDD

Completed · Phase 2/Phase 3

Conditions studied: Primary Immunodeficiency Diseases (PID)

In brief

The purpose of this study is to develop a 20% subcutaneous (SC) immunoglobulin preparation for the treatment of patients with primary immunodeficiency diseases (PIDD).

Key facts

Study ID
NCT01218438
Run by
Baxalta now part of Shire
People needed
86
Starts
2013-01-28
Expected to finish
2015-03-13
Last updated by the study team
2021-07-20

Who can join

Age: 2 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.